Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S MARGOLIN

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
British Journal of Cancer|September 13, 2007
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancerB Song, S Margolin, J Skoglund, et al.
Journal of Medical Genetics|May 10, 2005
High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancerM Kristiansen, G P S Knudsen, P Maguire, et al.
International Journal of Immunopharmacology|January 7, 1999
Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidoneW C Cain, R W Stuart, D L Lefkowitz, et al.
Nucleic Acids Research|June 15, 1997
Expression of herpes virus thymidine kinase in Neurospora crassaM S Sachs, E U Selker, B Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
Induction and maintenance of nonsymmetrical DNA methylation in NeurosporaEric U Selker, Michael Freitag, Gregory O Kothe, et al.
Nature|April 25, 2003
The methylated component of the Neurospora crassa genomeEric U Selker, Nikolaos A Tountas, Sally H Cross, et al.
Genetics|August 5, 1998
A methylated Neurospora 5S rRNA pseudogene contains a transposable element inactivated by repeat-induced point mutationB S Margolin, P W Garrett-Engele, J N Stevens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 20, 2021
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trialW He, M Eriksson, E Eliasson, et al.
Journal of Health Politics, Policy and Law|April 11, 2002
Evaluating partnerships for community health improvement: tracking the footprintsStephen M Shortell, Ann P Zukoski, Jeffrey A Alexander, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|September 13, 2007
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancerB Song, S Margolin, J Skoglund, et al.
Journal of Medical Genetics|May 10, 2005
High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancerM Kristiansen, G P S Knudsen, P Maguire, et al.
International Journal of Immunopharmacology|January 7, 1999
Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidoneW C Cain, R W Stuart, D L Lefkowitz, et al.
Nucleic Acids Research|June 15, 1997
Expression of herpes virus thymidine kinase in Neurospora crassaM S Sachs, E U Selker, B Lin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
Induction and maintenance of nonsymmetrical DNA methylation in NeurosporaEric U Selker, Michael Freitag, Gregory O Kothe, et al.
Nature|April 25, 2003
The methylated component of the Neurospora crassa genomeEric U Selker, Nikolaos A Tountas, Sally H Cross, et al.
Genetics|August 5, 1998
A methylated Neurospora 5S rRNA pseudogene contains a transposable element inactivated by repeat-induced point mutationB S Margolin, P W Garrett-Engele, J N Stevens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 20, 2021
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trialW He, M Eriksson, E Eliasson, et al.
Journal of Health Politics, Policy and Law|April 11, 2002
Evaluating partnerships for community health improvement: tracking the footprintsStephen M Shortell, Ann P Zukoski, Jeffrey A Alexander, et al.
British Journal of Haematology|July 27, 2001
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaR A Mesa, A Tefferi, M A Elliott, et al.
Pageof 3